Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is one of six new Oxford-Celgene Fellowships, which give postdoctoral researchers exposure to the field of commercial drug discovery and development.

Ruxandra Dafinca
I feel very lucky to have been awarded an Oxford-Celgene Fellowship and I am excited to start working on my project which will hopefully uncover new therapeutic targets involved in neuronal transport defects in ALS.
- Ruxandra Dafinca

The Oxford-Celgene Fellowship Programme was established in 2015 with the aim of stimulating new scientific discovery and translation and to facilitate skills and people transfer between researchers in academia and industry.

Oxford’s relationship with Celgene continues to grow year on year, with the new 2019 Fellowships taking the total of Oxford-Celgene Fellows to 22. The new Fellowships represent an additional investment of £3M into the University.

Ruxandra Dafinca models amyotrophic lateral sclerosis (ALS or motor neuron disease) in neurons obtained by differentiating induced pluripotent stem cells (iPSCs) derived from patients. 

During her three-year research project she will collaborate with Celgene scientists, benefit from mentorship and training, and visit facilities at Celgene labs in the US and Spain.

Ruxandra is interested in a particular mutation found in ALS motor neurons. The protein TDP-43 is found in the wrong compartment of the cell in 97 per cent of ALS cases. She wants to understand what drives this change. Using microscopy and mouse models, she will investigate how transport both in and out of the nucleus, and across the cell, is generally different in patient cells compared to healthy neurons.

In year two of her project, Ruxandra hopes to use her understanding of how the protein is disregulated to begin screening for drugs that are able to restore normal function. She is excited about the potential of this work, which is based on good preliminary data.

Similar stories

New genetic diagnosis technology for eye disease receives major funding award

Eye2Gene explores the use of AI to determine which genetic condition is causing a patient’s inherited retinal disease, by examining eye scans.

Royal Commission Industrial Fellowship for Andrei-Claudiu Roibu with F. Hoffmann-La Roche Ltd

Mapping brain network activity from structural connectivity using deep learning

Researchers awarded Wellcome Innovator Grant to investigate role of brainstem nucleus in human consciousness

Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.

How our dreams changed during the COVID-19 pandemic

This study explored associations between COVID-19 and dream recall frequency, and related social, health, and mental health factors.

New insights into the effect of exposure to dim light in the evening on the biology of the sleep-wake cycle

A new study has revealed more about how exposure to dim light in the evening affects circadian health. The findings emphasise the need to optimise our artificial light exposure if we are to avoid shifting our biological clocks.

Blood lipoprotein levels linked to future risk of amyotrophic lateral sclerosis

Greater understanding of the role of lipoproteins could support screening and efforts to develop treatments.